Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Martinelli G, Iacobucci I, Rosti G, Pane F, Amabile M, Castagnetti F, Cilloni D, Soverini S, Testoni N, Specchia G, Merante S, Zaccaria A, Frassoni F, Saglio G, Baccarani M. Martinelli G, et al. Among authors: baccarani m. Ann Oncol. 2006 Mar;17(3):495-502. doi: 10.1093/annonc/mdj106. Epub 2006 Jan 10. Ann Oncol. 2006. PMID: 16403813 Free article.
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.
Iacobucci I, Lonetti A, Messa F, Ferrari A, Cilloni D, Soverini S, Paoloni F, Arruga F, Ottaviani E, Chiaretti S, Messina M, Vignetti M, Papayannidis C, Vitale A, Pane F, Piccaluga PP, Paolini S, Berton G, Baruzzi A, Saglio G, Baccarani M, Foà R, Martinelli G. Iacobucci I, et al. Among authors: baccarani m. Leukemia. 2010 Jan;24(1):66-73. doi: 10.1038/leu.2009.197. Epub 2009 Sep 17. Leukemia. 2010. PMID: 19759560
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM. Giles FJ, et al. Among authors: baccarani m. Leukemia. 2010 Jul;24(7):1299-301. doi: 10.1038/leu.2010.110. Epub 2010 Jun 3. Leukemia. 2010. PMID: 20520639 Free PMC article. Clinical Trial.
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis.
Soverini S, Score J, Iacobucci I, Poerio A, Lonetti A, Gnani A, Colarossi S, Ferrari A, Castagnetti F, Rosti G, Cervantes F, Hochhaus A, Delledonne M, Ferrarini A, Sazzini M, Luiselli D, Baccarani M, Cross NC, Martinelli G. Soverini S, et al. Among authors: baccarani m. Leukemia. 2011 Jan;25(1):178-81. doi: 10.1038/leu.2010.236. Epub 2010 Oct 21. Leukemia. 2011. PMID: 20962862 No abstract available.
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Giles FJ, et al. Among authors: baccarani m. Leukemia. 2013 Jan;27(1):107-12. doi: 10.1038/leu.2012.181. Epub 2012 Jul 5. Leukemia. 2013. PMID: 22763385 Clinical Trial.
777 results